



Betamethasone (0.05%) Cream Formulation

Versio 3.5	n Revision Date: 09.04.2021	SDS Number: 1685840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
SEC1	TION 1: Identification o	f the substance/m	nixture and of the company/undertaking
	oduct identifier Trade name	: Betamethaso	ne (0.05%) Cream Formulation
1.2 Re	elevant identified uses of	the substance or n	nixture and uses advised against
-	lse of the Sub- tance/Mixture	: Pharmaceutic	al
1.3 De	etails of the supplier of th	ne safety data sheet	
С	Company		o. reet, 33nd floor / City, New Jersey, U.S.A
Т	elephone	: 551-430-6000)
	-mail address of person esponsible for the SDS	: EHSSTEWAF	RD@organon.com
445		h	

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B Specific target organ toxicity - repeated exposure, Category 1 Long-term (chronic) aquatic hazard, Cat- egory 1	H360D: May damage the unborn child.H372: Causes damage to organs through prolonged or repeated exposure.H410: Very toxic to aquatic life with long lasting effects.
--	---

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	
Signal word	:	Danger
Hazard statements	:	 H360D May damage the unborn child. H372 Causes damage to organs through prolonged or repeated exposure. H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements	:	Prevention:

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 1685840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
		P264 Wash skir P273 Avoid rele	ecial instructions before use. In thoroughly after handling. Pase to the environment. Protective gloves/ protective clothing/ eye protec- on.
		Response: P308 + P313 IF attention. P391 Collect sp	exposed or concerned: Get medical advice/

Hazardous components which must be listed on the label:

betamethasone

Additional Labelling

EUH208 Contains 4-Chloro-3-methylphenol. May produce an allergic reaction.

2.3 Other hazards

This substance/mixture contains components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB).

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
4-Chloro-3-methylphenol	59-50-7 200-431-6 604-014-00-3	Acute Tox. 4; H302 Acute Tox. 4; H312 Skin Corr. 1C; H314 Eye Dam. 1; H318 Skin Sens. 1B; H317 STOT SE 3; H335 Aquatic Acute 1; H400 Aquatic Chronic 3; H412 M-Factor (Acute aquatic toxicity): 1	0.1

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation


sion	Revision Date: 09.04.2021	SDS Number: 1685840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017	
betame	ethasone	378-44-9 206-825-4	Acute toxicity estimateAcute dermal toxicity:1,100 mg/kgAcute Tox. 2; H330Acute Tox. 2; H330STOT RE 1; H372(Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)Aquatic Chronic 1;H410M-Factor (Chronic aquatic toxicity):1,000specific concentration limitSTOT RE 1; H372>= 0.01 %Repr. 1B; H360D>= 0.01 %	64
PBT an	d vPvB substance :			
Decam	ethylcyclopentasiloxan	e 541-02-6 208-764-9	7	

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes.





Version 3.5	Revision Date: 09.04.2021		S Number: 85840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
			Get medical atte Wash clothing b Thoroughly clea	
In cas	e of eye contact	:		water as a precaution. Intion if irritation develops and persists.
lf swa	llowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.	
4.2 Most iı	mportant symptoms a	nd e	effects, both acu	te and delayed
Risks		:	May damage the Causes damage exposure.	e unborn child. to organs through prolonged or repeated
			May produce an	allergic reaction.
4.3 Indicat	tion of any immediate	meo	dical attention ar	nd special treatment needed
Treatr	ment	:	Treat symptoma	tically and supportively.
Suitab	uishing media ble extinguishing media	:	Water spray Alcohol-resistan Carbon dioxide Dry chemical	
Unsui media	table extinguishing a	:	None known.	
5.2 Specia	al hazards arising from	n the	e substance or m	nixture
Specil fightin	fic hazards during fire- g	:		rm explosive mixtures with air. nbustion products may be a hazard to health.
Hazar ucts	dous combustion prod-	:	Carbon oxides Silicon oxides Formaldehyde	
5.3 Advice	e for firefighters			
	al protective equipment efighters	:		re, wear self-contained breathing apparatus. otective equipment.
Specif ods	fic extinguishing meth-	:	cumstances and Use water spray	ng measures that are appropriate to local cir- I the surrounding environment. I to cool unopened containers. aged containers from fire area if it is safe to de

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 1685840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017					
		Evacuate area.						
SECTION	SECTION 6: Accidental release measures							
6.1 Persor	nal precautions, prote	ective equipment and	l emergency procedures					
Perso	nal precautions	Follow safe han	rotective equipment. Idling advice (see section 7) and personal pro- ent recommendations (see section 8).					
6.2 Enviro	nmental precautions							
Environmental precautions		Prevent further Retain and disp Local authorities	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.					
6.3 Metho	ds and material for co	ontainment and clear	ning up					
Metho	ods for cleaning up	tainer for dispos Local or nationa posal of this ma employed in the mine which regu Sections 13 and	cuum up spillage and collect in suitable con- sal. al regulations may apply to releases and dis- terial, as well as those materials and items e cleanup of releases. You will need to deter- ulations are applicable. d 15 of this SDS provide information regarding national requirements.					
6 4 Refere	nce to other sections							


6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	 Do not get on skin or clothing. Do not breathe dust, fume, gas, mist, vapours or spray. Do not swallow. Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the
Hygiene measures	 environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working





Betamethasone (0.05%) Cream Formulation

Version 3.5	Revision Date: 09.04.2021		DS Number: 85840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
			nated clothing be The effective ope engineering contr appropriate dego	ration of a facility should include review of ols, proper personal protective equipment, wning and decontamination procedures, monitoring, medical surveillance and the
7.2 Cond	itions for safe storage,	inc	luding any incom	patibilities
•	uirements for storage s and containers	:		abelled containers. Store locked up. Keep ore in accordance with the particular national
Advi	ce on common storage	:	Do not store with Strong oxidizing a Organic peroxide Explosives Gases	•
7.3 Speci	fic end use(s)			
Spec	cific use(s)	:	No data available	

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis		
Petrolatum	8009-03-8	OELV - 8 hrs (TWA) (inhalable fraction)	5 mg/m3	IE OEL		
	Further inform	nation: Where no spe	cific short-term exposure lim	it is listed, a		
	figure three tir	mes the long-term ex	posure limit value should be	eused		
Propylene glycol	57-55-6	OELV - 8 hrs (TWA) (particles)	10 mg/m3	IE OEL		
	Further inform	nation: Where no spe	cific short-term exposure lim	it is listed, a		
			posure limit value should be			
	OELV - 8 hrs 150 ppm IE OEI					
		(TWA) (total (va-	470 mg/m3			
		pour and parti- cles))				
		cific short-term exposure lim posure limit value should be				
Glyceryl monos- tearate	123-94-4	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL		
	Further inform	nation: Where no spe	cific short-term exposure lim	it is listed, a		
	figure three times the long-term exposure limit value should be used					
betamethasone	378-44-9	TWA	1 µg/m3 (OEB 4)	Internal		
	Further inform	Further information: Skin				
		Wipe limit	10 μg/100 cm²	Internal		

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	1685840-00009	Date of first issue: 17.05.2017

Occupational exposure limits of decomposition products

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis					
Formaldehyde	50-00-0	OELV - 15 min	0.6 ppm	IE OEL					
		(STEL)	0.738 mg/m3						
			nts which following exposure						
			t and lead to asthma, rhinitis						
			ances presumed to have car	cinogenic po-					
	tential for hur	tential for humans							
		OELV - 8 hrs	0.3 ppm	IE OEL					
		(TWA)	0.37 mg/m3						
	Further inform	Further information: Chemical agents which following exposure may cause							
	sensitisation of the respiratory tract and lead to asthma, rhinitis or extrinsic								
		allergic alveolitis, Carc 1B - Substances presumed to have carcinogenic po-							
	U U	tential for humans							
		STEL	0.6 ppm	2004/37/EC					
1			0.74 mg/m3						
	Further inform	Further information: Dermal sensitisation, Carcinogens or mutagens							
		TWA	0.3 ppm	2004/37/EC					
			0.37 mg/m3						
	Further inform	Further information: Dermal sensitisation, Carcinogens or mutagens							

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

	· /		(20) 110: 100/12000.	
Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Decamethylcyclopen- tasiloxane	Workers	Inhalation	Long-term systemic effects	97.3 mg/m3
	Workers	Inhalation	Acute systemic ef- fects	62 mg/m3
	Workers	Inhalation	Long-term local ef- fects	24.2 mg/m3
	Consumers	Inhalation	Long-term systemic effects	17.3 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	4.3 mg/m3
	Consumers	Ingestion	Long-term systemic effects	5 mg/kg bw/day
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3
4-Chloro-3- methylphenol	Workers	Inhalation	Long-term systemic effects	6.289 mg/m3
	Workers	Skin contact	Long-term systemic effects	3.567 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1.551 mg/m3

according to Regulation (EC) No. 1907/2006



0.892 mg/kg

h.v./da

Long-term systemic

- 44 -

Betamethasone (0.05%) Cream Formulation

Consumers

Version 3.5	Revision Date: 09.04.2021	SDS Numl 1685840-0			f last issue: 10.10.2020 f first issue: 17.05.2017	
		Consumers	Skin conta	act	Long-term systemic effects	1.783 mg/kg bw/day

			enecis	bw/day
Predicted No Effect Co	oncentration (PN	FC) according to I	Regulation (FC) No. 19	07/2006

Ingestion

Predicted No Effect Concentrat	ion (PNEC) according to Regulation (EC) N	0. 1907/2006:
Substance name	Environmental Compartment	Value
Petrolatum	Oral (Secondary Poisoning)	9.33 mg/kg food
Decamethylcyclopentasiloxane	Sewage treatment plant	10 mg/l
	Fresh water sediment	11 mg/kg
	Marine sediment	1.1 mg/kg
	Soil	3.77 mg/kg
	Oral (Secondary Poisoning)	13 mg/kg food
Propylene glycol	Fresh water	260 mg/l
	Marine water	26 mg/l
	Intermittent use/release	183 mg/l
	Sewage treatment plant	20000 mg/l
	Fresh water sediment	572 mg/kg
	Marine sediment	57.2 mg/kg
	Soil	50 mg/kg
4-Chloro-3-methylphenol	Fresh water	0.015 mg/l
	Intermittent use/release	0.015 mg/l
	Marine water	0.002 mg/l
	Sewage treatment plant	2.286 mg/l
	Fresh water sediment	13.981 mg/kg dry weight (d.w.)
	Marine sediment	13.981 mg/kg dry weight (d.w.)
	Soil	6.399 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		

Material : Chemical-resistant gloves

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 1685840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017	
Remarks Skin and body protection		 Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potential contaminated clothing. 		
Respi	ratory protection	sure assessm ommended gu	cal exhaust ventilation is not available or expo- ent demonstrates exposures outside the rec- idelines, use respiratory protection. buld conform to I.S. EN 14387	
Filt	ter type	• •	ticulates, inorganic gas/vapour and organic	

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state Colour Odour Odour Threshold	:	cream white No data available No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	> 93.3 °C
Auto-ignition temperature	:	No data available
Decomposition temperature Decomposition tempera- ture	:	No data available
рН	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n- octanol/water	:	Not applicable

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Vers 3.5	ion	Revision Date: 09.04.2021		S Number: 35840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
Vapour pressure		:	No data available	e	
	Relativ	e density	:	No data available	e
	Density	/	:	No data available	e
	Relativ	e vapour density	:	Not applicable	
		e characteristics ticle size	:	Not applicable	
9.2 0	Other ir	nformation			
	Explos	ives	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Evapor	ration rate	:	Not applicable	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

Hazardous reactions	:	Vapours may form explosive mixture with air. Can react with strong oxidizing agents. Hazardous decomposition products will be formed at elevated temperatures.		
10.4 Conditions to avoid				
Conditions to avoid	:	None known.		
10.5 Incompatible materials				
Materials to avoid	:	Oxidizing agents		
10.6 Hazardous decomposition products				

Thermal decomposition : Formaldehyde

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of	:	Skin contact
exposure		Ingestion
		Eye contact

according to Regulation (EC) No. 1907/2006



rsion 5	Revision Date: 09.04.2021		Number: 340-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017			
Acute	e toxicity						
Not cl	assified based on ava	ilable info	ormation.				
<u>Comp</u>	oonents:						
4-Chl	oro-3-methylphenol:						
Acute	oral toxicity	: LC	050 (Mouse):	600 mg/kg			
Acute	inhalation toxicity	: LC50 (Rat): > 2.871 mg/l Exposure time: 4 h Test atmosphere: dust/mist					
Acute	dermal toxicity	Me Re	ethod: Exper	ed on harmonised classification in EU regulation			
betan	nethasone:						
Acute	oral toxicity	: LC	050 (Rat): > 5	5,000 mg/kg			
		LC)50 (Mouse):	> 4,500 mg/kg			
Acute	inhalation toxicity		C50 (Rat): 0.4 (posure time:				
Deca	methylcyclopentasil	oxane:					
Acute	oral toxicity	: LC	050 (Rat): > 5	5,000 mg/kg			
Acute	inhalation toxicity	E× Te	: LC50 (Rat): 8.67 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: OECD Test Guideline 403				
Acute	dermal toxicity	As		> 2,000 mg/kg he substance or mixture has no acute dermal			
-	corrosion/irritation	ilable info	ormation.				
<u>Com</u>	oonents:						
4-Chl	oro-3-methylphenol:						
Speci			abbit				
Metho Resul			ECD Test Gu prrosive after	Ideline 404 1 to 4 hours of exposure			
hetan	nethasone:						
Speci		: Ra	abbit				
Resul			ld skin irritati	on			

according to Regulation (EC) No. 1907/2006



	Revision Date: 09.04.2021	SDS Number: 1685840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
Decan	nethylcyclopentasi	loxane:	
Specie	es	: Rabbit	
Result		: No skin irritatio	n
Seriou	ıs eye damage/eye	irritation	
Not cla	assified based on ava	ailable information.	
<u>Comp</u>	onents:		
4-Chlo	oro-3-methylphenol	:	
Specie	S	: Rabbit	
Metho	d	: OECD Test Gu	ideline 405
Result		: Irreversible effe	ects on the eye
hetam	ethasone:		
Specie		: Rabbit	
Result		: No eye irritation	
Nesuit		. No eye imailoi	1
Decan	nethylcyclopentasi	loxane:	
Specie	es	: Rabbit	
Result		: No eye irritatior	า
-	ratory or skin sensi ensitisation	itisation	
Skin s Not cla Respir	ensitisation assified based on ava ratory sensitisation	ailable information.	
Skin s Not cla Respin Not cla	ensitisation assified based on ava ratory sensitisation assified based on ava	ailable information.	
Skin s Not cla Respin Not cla	ensitisation assified based on ava ratory sensitisation	ailable information.	
Skin s Not cla Respin Not cla <u>Comp</u> 4-Chlo	ensitisation assified based on avainatory sensitisation assified based on avaination onents: pro-3-methylphenol	ailable information. ailable information.	
Skin s Not cla Respin Not cla <u>Comp</u> 4-Chlo Test T	ensitisation assified based on avainatory sensitisation assified based on avainatory onents: pro-3-methylphenol ype	ailable information. ailable information. : : Maximisation T	est
Skin s Not cla Respin Not cla <u>Comp</u> 4-Chlo Test T Expose	ensitisation assified based on avainatory sensitisation assified based on avainatory onents: pro-3-methylphenol ype ure routes	ailable information. ailable information. : : : Maximisation T : Skin contact	est
Skin s Not cla Respin Not cla <u>Comp</u> 4-Chlo Test T	ensitisation assified based on avainatory sensitisation assified based on avainatory onents: pro-3-methylphenol ype ure routes	ailable information. ailable information. : : Maximisation T	est
Skin s Not cla Respin Not cla <u>Comp</u> 4-Chlo Test T Expose	ensitisation assified based on avainatory sensitisation assified based on avainatory onents: oro-3-methylphenol ype ure routes as	ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig	vidence of low to moderate skin sensitisatio
Skin s Not cla Respin Not cla <u>Comp</u> 4-Chlo Test T Exposi Specie Assess	ensitisation assified based on avainatory sensitisation assified based on avainatory onents: oro-3-methylphenol ype ure routes as	ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig : Probability or e	vidence of low to moderate skin sensitisation
Skin s Not cla Respin Not cla Comp 4-Chic Test T Expose Specie Assess betam	ensitisation assified based on avainatory sensitisation assified based on avainatory conents: pro-3-methylphenol ype ure routes sment sment	ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig : Probability or e rate in humans	vidence of low to moderate skin sensitisation
Skin s Not cla Respin Not cla Comp 4-Chlo Test T Expose Specie Assess betam Expose	ensitisation assified based on avainatory sensitisation assified based on avainatory sensitisation assified based on avainator onents: oro-3-methylphenol ype ure routes assiment ethasone: ure routes	ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig : Probability or e rate in humans : Dermal	vidence of low to moderate skin sensitisation
Skin s Not cla Respin Not cla Comp 4-Chic Test T Expose Specie Assess betam	ensitisation assified based on avainatory sensitisation assified based on avainatory sensitisation assified based on avainator onents: oro-3-methylphenol ype ure routes assiment ethasone: ure routes as	ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig : Probability or e rate in humans	vidence of low to moderate skin sensitisatio
Skin s Not cla Respin Not cla <u>Comp</u> 4-Chlo Test T Exposi Specie Assess betam Exposi Specie Result	ensitisation assified based on avainatory sensitisation assified based on avainatory onents: oro-3-methylphenol ype ure routes assiment ethasone: ure routes as	ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig : Probability or e rate in humans : Dermal : Guinea pig : Weak sensitize	vidence of low to moderate skin sensitisatio
Skin s Not cla Respin Not cla Comp 4-Chic Test T Expose Specie Assess betam Expose Specie Result	ensitisation assified based on avainatory sensitisation assified based on avainators onents: oro-3-methylphenol ype ure routes assiment ethasone: ure routes as	ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig : Probability or e rate in humans : Dermal : Guinea pig : Weak sensitize	vidence of low to moderate skin sensitisatio
Skin s Not cla Respin Not cla Comp 4-Chic Test T Expose Specie Assess betam Expose Specie Result Decan Test T	ensitisation assified based on avaination assified based on avaination assified based on avaination onents: oro-3-methylphenol ype ure routes assiment ethasone: ure routes as methylcyclopentasi	ailable information. ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig : Probability or e rate in humans : Dermal : Guinea pig : Weak sensitize loxane: : Local lymph no	vidence of low to moderate skin sensitisatio
Skin s Not cla Respin Not cla Comp 4-Chic Test T Expose Specie Assess betam Expose Specie Result Decan Test T	ensitisation assified based on avainatory sensitisation assified based on avainatory onents: oro-3-methylphenol ype ure routes assiment ethasone: ure routes as methylcyclopentasil ype ure routes	ailable information. ailable information. : : Maximisation T : Skin contact : Guinea pig : Probability or e rate in humans : Dermal : Guinea pig : Weak sensitize	vidence of low to moderate skin sensitisatio

according to Regulation (EC) No. 1907/2006



Version 3.5	Revision Date: 09.04.2021		S Number: 5840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
	r m cell mutagenicity t classified based on avail	lable ir	nformation.	
<u>Co</u>	mponents:			
4-0	Chloro-3-methylphenol:			
Ge	notoxicity in vitro		Test Type: Bacte Result: negative	rial reverse mutation assay (AMES)
be	tamethasone:			
Ge	notoxicity in vitro		Test Type: Bacte Result: negative	rial reverse mutation assay (AMES)
			Test Type: In vitro Result: negative	o mammalian cell gene mutation test
			Test Type: Chron Result: positive	nosome aberration test in vitro
Ge	notoxicity in vivo		Test Type: Mamn cytogenetic assay Species: Mouse Application Route Result: equivocal	
	rm cell mutagenicity- As- ssment		Weight of evidend cell mutagen.	ce does not support classification as a germ
De	camethylcyclopentasilo	xane:		
Ge	notoxicity in vitro			rial reverse mutation assay (AMES) est Guideline 471
				nosome aberration test in vitro est Guideline 473
			Test Type: In vitro Result: negative	o mammalian cell gene mutation test
Ge	notoxicity in vivo		cytogenetic assay Species: Rat Application Route	nalian erythrocyte micronucleus test (in vivo /) e: inhalation (vapour) est Guideline 474
			mammalian liver Species: Rat Application Route	

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020	
3.5	09.04.2021	1685840-00009	Date of first issue: 17.05.2017	

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage the unborn child.

Components:

4-Chloro-3-methylphenol:	
Effects on fertility :	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal develop- : ment	Test Type: Reproduction/Developmental toxicity screening test Species: Rat Application Route: Ingestion Result: negative
betamethasone:	
Effects on foetal develop- : ment	Species: Rabbit Application Route: Intramuscular Developmental Toxicity: LOAEL: 0.05 mg/kg body weight Result: Fetotoxicity, Malformations were observed.
	Species: Rat Application Route: Subcutaneous Developmental Toxicity: LOAEL: 0.42 mg/kg body weight Result: Malformations were observed.
	Species: Mouse Application Route: Intramuscular Developmental Toxicity: LOAEL: 1 mg/kg body weight Result: Malformations were observed.
Reproductive toxicity - As- : sessment	Clear evidence of adverse effects on development, based on animal experiments.
Decamethylcyclopentasiloxane	
Effects on fertility :	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: inhalation (vapour) Method: OPPTS 870.3800 Result: negative
Effects on foetal develop- : ment	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: inhalation (vapour) Method: OPPTS 870.3800 Result: negative

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Version 3.5	Revision Date: 09.04.2021	SDS Number: 1685840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
STO	T - single exposure		
Not c	classified based on ava	ilable information.	
<u>Com</u>	ponents:		
4-Ch	loro-3-methylphenol:	-	
Asse	ssment	: May cause re	espiratory irritation.
STO.	T - repeated exposure	2	
	ses damage to organs		r repeated exposure.
	ponents:		
beta	methasone:		
Targe	et Organs	: Pituitary glan Adrenal glan	d, Immune system, muscle, thymus gland, Blood, d
Asse	ssment	5	age to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

4-Chloro-3-methylphenol:

Species:RatNOAEL:200 mg/kgLOAEL:400 mg/kgApplication Route:IngestionExposure time:28 Daysbetamethasone:Species:RabbitLOAEL:LOAEL:0.05 %Application Route:Skin contactExposure time:10 - 30 dTarget Organs:Pituitary gland, Immune system, muscleSpecies:RatLOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contact:Exposure time:Species:DogLOAELLOAEL:DogLOAELCOAEL:DogLOAELLOAEL:LOAEL:LOAEL:LOAEL:LOAEL:LOAEL:LOAEL:LOAEL:LOAEL:LOAEL:LOAEL:LOAEL:<	4-Chloro-3-methylphenol:	
LOAEL : 400 mg/kg Application Route : Ingestion Exposure time : 28 Days betamethasone: Species : Rabbit LOAEL : 0.05 % Application Route : Skin contact Exposure time : 10 - 30 d Target Organs : Pituitary gland, Immune system, muscle Species : Rat LOAEL : 0.05 % Application Route : Skin contact Exposure time : 8 Weeks Target Organs : thymus gland Species : Mouse LOAEL : 0.1 % Application Route : Skin contact Exposure time : 8 Weeks Target Organs : thymus gland Species : Mouse LOAEL : 0.1 % Application Route : Skin contact Exposure time : 8 Weeks Target Organs : thymus gland Species : Dog	Species	
Application Route Exposure time:Ingestion Exposurebetamethasone::28 Daysbetamethasone:::Species:Rabbit 1.0-5%LOAEL:0.05%Application Route:Skin contact Exposure timeExposure time:10 - 30 d 1 or 30 d Target OrgansSpecies:Rat 0.05%LOAEL:0.05% Mapplication RouteSpecies:Rat 1.0-5%LOAEL:0.05% Mapplication RouteSpecies:Rat 1.0-15%LOAEL:0.05% Mapplication RouteSpecies:Mouse 1.0-1%LOAEL:0.1% Mapplication RouteSpecies:Mouse 1.0-1%LOAEL:0.1% Mapplication RouteSpecies:Skin contact 1.0-1%Application Route:Skin contact 2.0-1%Exposure time:8 Weeks 1.1-200000000000000000000000000000000000		
Exposure time: 28 Daysbetamethasone:Species: RabbitLOAEL: 0.05 %Application Route: Skin contactExposure time: 10 - 30 dTarget Organs: Pituitary gland, Immune system, muscleSpecies: RatLOAEL: 0.05 %Application Route: Skin contactExposure time: 8 WeeksTarget Organs: thymus glandSpecies: MouseLOAEL: 0.1 %Application Route: Skin contactExposure time: 8 WeeksTarget Organs: thymus glandSpecies: MouseLOAEL: 0.1 %Application Route: Skin contactExposure time: 8 WeeksTarget Organs: thymus glandSpecies: Dog		
betamethasone:Species:RabbitLOAEL:0.05 %Application Route:Skin contactExposure time:10 - 30 dTarget Organs:Pituitary gland, Immune system, muscleSpecies:RatLOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	• •	
Species:RabbitLOAEL:0.05 %Application Route:Skin contactExposure time:10 - 30 dTarget Organs:Pituitary gland, Immune system, muscleSpecies:RatLOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	Exposure time	28 Days
Species:RabbitLOAEL:0.05 %Application Route:Skin contactExposure time:10 - 30 dTarget Organs:Pituitary gland, Immune system, muscleSpecies:RatLOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	betamethasone:	
LOAEL:0.05 %Application Route:Skin contactExposure time:10 - 30 dTarget Organs:Pituitary gland, Immune system, muscleSpecies:RatLOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog		· Rabbit
Application Route:Skin contactExposure time:10 - 30 dTarget Organs:Pituitary gland, Immune system, muscleSpecies:RatLOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	•	
Exposure time:10 - 30 dTarget Organs:Pituitary gland, Immune system, muscleSpecies:RatLOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	-	
Species:RatLOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog		: 10 - 30 d
LOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	Target Organs	: Pituitary gland, Immune system, muscle
LOAEL:0.05 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	Species	: Rat
Exposure time:8 WeeksTarget Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog		: 0.05 %
Target Organs:thymus glandSpecies:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog		
Species:MouseLOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	•	
LOAEL:0.1 %Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	Target Organs	: thymus gland
Application Route:Skin contactExposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	Species	: Mouse
Exposure time:8 WeeksTarget Organs:thymus glandSpecies:Dog	LÕAEL	: 0.1 %
Target Organs:thymus glandSpecies:Dog		
Species : Dog		
	Target Organs	: thymus gland
	Species	: Dog
	•	

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Version 3.5	Revision Date: 09.04.2021)S Number: 85840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
Expo	cation Route sure time et Organs	:	Oral 28 d Blood, thymus gla	and, Adrenal gland
Deca	methylcyclopentasilo	xane	:	
Speci NOAE LOAE Applio Metho	EL EL cation Route		Rat 1,000 mg/kg > 1,000 mg/kg Ingestion OECD Test Guide	eline 408

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

betamethasone:

Inhalation	:	Target Organs: Adrenal gland
Skin contact	:	Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

4-Chloro-3-methylphenol:		
Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 917 μg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 1.5 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	ErC50 (Chlorella pyrenoidosa (aglae)): 15 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
		EC10 (Chlorella pyrenoidosa (aglae)): 2.3 mg/l Exposure time: 72 h

according to Regulation (EC) No. 1907/2006




ersion 5	Revision Date: 09.04.2021		9S Number: 85840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
			Method: OECD T	Fest Guideline 201
M-Fac icity)	ctor (Acute aquatic tox-	:	1	
Toxici	ty to microorganisms	:	EC50 : 22.86 mg Exposure time: 6	
Toxici icity)	ty to fish (Chronic tox-	:		
	ty to daphnia and other ic invertebrates (Chron- city)	:		
betan	nethasone:			
	ty to daphnia and other ic invertebrates	:	EC50 (Americam Exposure time: 9	
Toxici plants	ty to algae/aquatic	:	mg/l Exposure time: 7 Method: OECD 1	rchneriella subcapitata (green algae)): > 34 2 h Fest Guideline 201 iicity at the limit of solubility
			mg/l Exposure time: 7 Method: OECD 1	irchneriella subcapitata (green algae)): 34 2 h Fest Guideline 201 iicity at the limit of solubility
Toxici icity)	ty to fish (Chronic tox-	:		
	ty to daphnia and other ic invertebrates (Chron- city)	:		1 d a magna (Water flea) Fest Guideline 211
M-Fac toxicit	ctor (Chronic aquatic y)	:	1,000	
	nethylcyclopentasilox	ane	:	
	ty to fish	:		chus mykiss (rainbow trout)): > 16 µg/l

according to Regulation (EC) No. 1907/2006



Vers 3.5	sion	Revision Date: 09.04.2021		0S Number: 85840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017	
				Exposure time: 90 Remarks: No toxi	6 h city at the limit of solubility	
Toxicity to daphnia and other aquatic invertebrates		:	Exposure time: 48 Method: OECD T	nagna (Water flea)): > 2.9 μg/l 3 h est Guideline 202 city at the limit of solubility		
	Toxicity to algae/aquatic plants		:	µg/l Exposure time: 96 Method: OECD T		
				µg/l Exposure time: 96 Method: OECD T		
	Toxicity	y to microorganisms	:	EC50 : > 2,000 m Exposure time: 3 Method: 88/302/E	ĥ	
	Toxicity to fish (Chronic tox- icity)		:	NOEC: 14 µg/l Exposure time: 90 d Species: Oncorhynchus mykiss (rainbow trout) Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility		
	Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)		:	NOEC: 15 μg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 Remarks: No toxicity at the limit of solubility		
12.2	Persis	tence and degradabil	ity			
	<u>Compo</u>	onents:				
		ro-3-methylphenol: radability	:	Result: Readily bi Biodegradation: Exposure time: 1 Method: OECD T	78 % 5 d	
	Decam	ethylcyclopentasilox	ane	:		
	Biodeg	radability	:	Result: Not readil Biodegradation: Exposure time: 28 Method: OECD T	0.14 %	





Version 3.5	Revision Date: 09.04.2021	-	S Number: 85840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
12.3 Bioa	ccumulative potential			
Com	oonents:			
4-Chl	oro-3-methylphenol:			
Bioac	cumulation	:		us carpio (Carp) n factor (BCF): 5.5 - 13
	ion coefficient: n- ol/water	:	log Pow: 0.477	
betar	nethasone:			
	ion coefficient: n- ol/water	:	log Pow: 2.11	
	methylcyclopentasilo	kane	:	
Bioac	cumulation	:	Bioconcentratio	hales promelas (fathead minnow) n factor (BCF): 7,060 - 13,300 Test Guideline 305
	ion coefficient: n- ol/water	:	log Pow: 8.023	
	lity in soil ata available			
12.5 Resu	lts of PBT and vPvB a	sses	ssment	
Prod	uct:			
Asses	ssment	:	be either persis	mixture contains components considered to tent, bioaccumulative and toxic (PBT), or very very bioaccumulative (vPvB).
<u>Com</u>	oonents:			
Deca	methylcyclopentasilo	kane	:	
Asses	ssment	:		
		:	This substance ing and toxic (P	is considered to be persistent, bioaccumulat- BT).
		:	This substance bioaccumulating	is considered to be very persistent and very g (vPvB).
12.6 Endo	ocrine disrupting prop	ertie	S	
Prod	uct:			
	ssment	:	ered to have en REACH Article	mixture does not contain components consid- docrine disrupting properties according to 57(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at or higher.
12.7 Othe	r adverse effects			
No da	ata available			

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	1685840-00009	Date of first issue: 17.05.2017

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number				
ADN	:	UN 3077		
ADR	:	UN 3077		
RID	:	UN 3077		
IMDG	:	UN 3077		
ΙΑΤΑ	:	UN 3077		
14.2 UN proper shipping name				
ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone)		
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone)		
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone)		
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone)		
ΙΑΤΑ	:	Environmentally hazardous substance, solid, n.o.s. (betamethasone)		
14.3 Transport hazard class(es)				
ADN	:	9		
ADR	:	9		
RID	:	9		
IMDG	:	9		
ΙΑΤΑ	:	9		
14.4 Packing group				

according to Regulation (EC) No. 1907/2006



Version 3.5	Revision Date: 09.04.2021		0S Number: 85840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017
Classi	ng group ification Code rd Identification Number s		III M7 90 9	
Classi Hazar Labels	ng group ification Code rd Identification Number s el restriction code	: : : : : : : : : : : : : : : : : : : :	III M7 90 9 (-)	
Classi	ng group ification Code d Identification Number s	: : : : : : : : : : : : : : : : : : : :	III M7 90 9	
IMDG Packir Labels EmS (ng group s	:	III 9 F-A, S-F	
Packii aircrat Packii	ng instruction (LQ) ng group	:	956 Y956 III Miscellaneous	
IATA Packii ger ai Packii	(Passenger) ng instruction (passen- rcraft) ng instruction (LQ) ng group	:	956 Y956 III Miscellaneous	
14.5 Envir	onmental hazards			
ADN Enviro	onmentally hazardous	:	yes	
ADR Enviro	onmentally hazardous	:	yes	
RID	onmentally hazardous	:	yes	
IMDG Marine	e pollutant	:	yes	
	(Passenger)	:	yes	
	(Cargo) onmentally hazardous	:	yes	



Betamethasone (0.05%) Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	1685840-00009	Date of first issue: 17.05.2017

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Decamethylcyclopentasiloxane (Number on list 70)
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Decamethylcyclopentasiloxane
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (ÉC) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

		Quantity 1	Quantity 2
E1	ENVIRONMENTAL	100 t	200 t
	HAZARDS		

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

according to Regulation (EC) No. 1907/2006



Betamethasone (0.05%) Cream Formulation

sion	Revision Date: 09.04.2021	-	OS Number: 85840-00009	Date of last issue: 10.10.2020 Date of first issue: 17.05.2017		
Other	information	:		nges have been made to the previous version the body of this document by two vertical		
Full te	ext of H-Statements					
H302		:	Harmful if swallow	wed.		
H312		:	Harmful in contac	ct with skin.		
H314		:	Causes severe s	kin burns and eye damage.		
H317		:		ergic skin reaction.		
H318		:	Causes serious e	eye damage.		
H330		:	Fatal if inhaled.			
H335		:	May cause respir			
H360E)	:	May damage the			
H372		:	exposure.	to organs through prolonged or repeated		
H400		:	Very toxic to aqu			
H410		:	Very toxic to aquatic life with long lasting effects.			
H412		:	: Harmful to aquatic life with long lasting effects.			
Full te	ext of other abbreviation	ons				
Acute		:	Acute toxicity			
	c Acute	:	Short-term (acute			
	c Chronic	:		nic) aquatic hazard		
Eye D	am.	:	Serious eye damage			
Repr.		:	Reproductive toxicity			
Skin C		:	Skin corrosion			
Skin S		:	Skin sensitisation			
STOT		:		gan toxicity - repeated exposure		
STOT		:		gan toxicity - single exposure		
2004/3	37/EC	:		2004/37/EC on the protection of workers ated to exposure to carcinogens or mutagen		
IE OE	L	:		nemical Agents and Occupational Exposure hedule 1		
2004/3	37/EC / STEL	•	Short term expos			
	37/EC / TWA	÷	Long term expos			
	L / OELV - 8 hrs (TWA)	:		oosure limit value (8-hour reference period)		
	L / OELV - 15 min	:		posure limit value (15-minute reference peri-		
(STEL			od)	,		

Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Miand Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO



Betamethasone (0.05%) Cream Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10.10.2020
3.5	09.04.2021	1685840-00009	Date of first issue: 17.05.2017

- International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

Classification of the mixtur	Classification procedure:	
Repr. 1B	H360D	Calculation method
STOT RE 1	H372	Calculation method
Aquatic Chronic 1	H410	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN